Histamine H3 Receptor Antagonists for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
| Autor: | Taro Kishi, Shinji Matsunaga, Momoko Kubo, Nakao Iwata |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Cochrane Library Placebo law.invention Randomized controlled trial law Alzheimer Disease Internal medicine medicine Humans Psychiatry Adverse effect Nootropic Agents Randomized Controlled Trials as Topic business.industry General Neuroscience General Medicine Discontinuation Psychiatry and Mental health Clinical Psychology Tolerability Relative risk Meta-analysis Geriatrics and Gerontology business Histamine H3 Antagonists |
| Zdroj: | Journal of Alzheimer's disease : JAD. 48(3) |
| ISSN: | 1875-8908 |
| Popis: | Background No comprehensive meta-analysis has been performed concerning the efficacy and tolerability of histamine H3 receptor antagonists (H3R-ANTs) in Alzheimer's disease patients. Objective We performed a systematic review and meta-analysis of double-blind randomized placebo-controlled trials (RCTs) of H3R-ANTs for Alzheimer's disease. Methods Relevant studies were identified through searches of PubMed, databases of the Cochrane Library, and PsycINFO citations up to June 19, 2015. The primary outcome was a change in the Mini-Mental State Examination (MMSE) scores. Secondary outcomes were Neuropsychiatric Inventory (NPI) scores, discontinuation rate, and individual adverse events/side effects. Risk ratios, numbers-needed-to-treat/harm, and standardized mean differences were calculated based on a random effects model. Results The computerized search initially yielded 33 studies after excluding duplicates. We excluded 29 of these articles following a review of titles and abstracts and one RCT including healthy subjects after full-text review. We identified three RCTs (two on GSK239512 and one on ABT-288) including 402 patients. Pooled H3R-ANTs were not superior to placebo for improvement in MMSE and NPI scores. Discontinuation rate and individual adverse events/side effects did not differ among the pooled groups. Conclusions Our results suggest that H3R-ANTs are not effective in treating cognitive dysfunction in Alzheimer's disease. However, further studies with larger samples are required for definitive conclusions regarding responsive subpopulations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|